Pleiotropic effects of HMG-CoA reductase inhibitors

被引:207
作者
Werner, N [1 ]
Nickenig, G [1 ]
Laufs, U [1 ]
机构
[1] Univ Saarlandes Kliniken, Med Klin & Poliklin, D-66421 Homburg, Germany
关键词
HMG CoA reductase inhibitiors; hypercholesterolemia; pleiotropic effects; review;
D O I
10.1007/s003950200000
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
HMG CoA reductase inhibitiors (statins) have been shown to be effective lipid lowering agents and are able to significantly reduce cardiovascular mortality and morbidity in patients at risk for cardiovascular disease. Recent clinical and experimental data suggest that the benefit of statins may extend beyond their hepatic effects on serum cholesterol levels. This review summarizes the current evidence and the molecular mechanisms of the direct effects of statins on plaque stability, inflammation, endothelial function, oxidative stress, thrombosis and stroke. Furthermore, recent data on the effects of statins on bone marrow, bone density and dementia are described. In summary, statins have emerged as a novel and powerful tool to study cardiovascular biology, including protein isoprenylation, small G protein function, leukocyte activity and endothelial progenitor cells. These pleiotropic properties of statins may have important clinical implications in addition to lowering serum cholesterol.
引用
收藏
页码:105 / 116
页数:12
相关论文
共 102 条
  • [1] Aikawa M, 2001, CIRCULATION, V103, P276
  • [2] Activation of RhoA by thrombin in endothelial hyperpermeability - Role of Rho kinase and protein tyrosine kinases
    Amerongen, GPV
    van Delft, S
    Vermeer, MA
    Collard, JG
    van Hinsbergh, VWM
    [J]. CIRCULATION RESEARCH, 2000, 87 (04) : 335 - 340
  • [3] Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice
    Amin-Hanjani, S
    Stagliano, NE
    Yamada, M
    Huang, PL
    Liao, JK
    Moskowitz, MA
    [J]. STROKE, 2001, 32 (04) : 980 - 985
  • [4] THE EFFECT OF CHOLESTEROL-LOWERING AND ANTIOXIDANT THERAPY ON ENDOTHELIUM-DEPENDENT CORONARY VASOMOTION
    ANDERSON, TJ
    MEREDITH, IT
    YEUNG, AC
    FREI, B
    SELWYN, AP
    GANZ, P
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (08) : 488 - 493
  • [5] COMPARISON OF PROPERTIES OF 4 INHIBITORS OF 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE
    BLUM, CB
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1994, 73 (14) : D3 - D11
  • [6] HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells
    Bourcier, T
    Libby, P
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2000, 20 (02) : 556 - 562
  • [7] LIPID-LOWERING AND PLAQUE REGRESSION - NEW INSIGHTS INTO PREVENTION OF PLAQUE DISRUPTION AND CLINICAL EVENTS IN CORONARY-DISEASE
    BROWN, BG
    ZHAO, XQ
    SACCO, DE
    ALBERS, JJ
    [J]. CIRCULATION, 1993, 87 (06) : 1781 - 1791
  • [8] Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women
    Chan, KA
    Andrade, SE
    Boles, M
    Buist, DSM
    Chase, GA
    Donahue, JG
    Goodman, MJ
    Gurwitz, JH
    LaCroix, AZ
    Platt, R
    [J]. LANCET, 2000, 355 (9222) : 2185 - 2188
  • [9] PHARMACOLOGY OF COMPETITIVE INHIBITORS OF HMG-COA REDUCTASE
    CORSINI, A
    MAGGI, FM
    CATAPANO, AL
    [J]. PHARMACOLOGICAL RESEARCH, 1995, 31 (01) : 9 - 27
  • [10] HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data
    Crouse, JR
    Byington, RP
    Furberg, CD
    [J]. ATHEROSCLEROSIS, 1998, 138 (01) : 11 - 24